RevolutionLogo.png
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
October 22, 2023 02:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RevolutionLogo.png
Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting
October 13, 2023 11:50 ET | Revolution Medicines, Inc.
Revolution Medicines reports encouraging clinical data for both RMC-6236 and RMC-6291, two pioneering RAS(ON) Inhibitors, at 2023 Triple Meeting
RevolutionLogo.png
Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
October 04, 2023 16:05 ET | Revolution Medicines, Inc.
Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhibitor) Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m....
RevolutionLogo.png
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
September 19, 2023 07:00 ET | Revolution Medicines, Inc.
KRASG12D(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring the KRASG12D mutation, the most common driver of RAS-addicted human cancers ...
RevolutionLogo.png
Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
August 17, 2023 16:05 ET | Revolution Medicines, Inc.
Science Report on KRASG12C(ON)-Selective Inhibitors Provides Preclinical Proof-of-Principle for Company's RAS Innovation Engine and Broad Pipeline REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE...
RevolutionLogo.png
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
August 08, 2023 16:05 ET | Revolution Medicines, Inc.
Company to provide clinical updates for RMC-6236 at Triple (AACR-NCI-EORTC) Meeting and ESMO (European Society for Medical Oncology) Congress 2023 and initial clinical findings for RMC-6291 at Triple...
RevolutionLogo.png
Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
August 03, 2023 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
RevolutionLogo.png
Revolution Medicines to Participate in Upcoming Investor Conferences
June 08, 2023 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RevolutionLogo.png
Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit
May 24, 2023 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RevolutionLogo.png
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
May 08, 2023 16:02 ET | Revolution Medicines, Inc.
First Wave of Investigational RAS(ON) Inhibitors – RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) – progressing on plan Appointment of chief medical officer and key leaders across...